Stifel Nicolaus Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
TipRanks (Wed, 8-May 10:05 PM ET)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Mon, 6-May 4:01 PM ET)
PRNewswire (Thu, 2-May 7:00 AM ET)
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
PRNewswire (Thu, 18-Apr 8:00 AM ET)
PRNewswire (Thu, 11-Apr 8:00 AM ET)
PRNewswire (Fri, 23-Feb 8:00 AM ET)
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
PRNewswire (Thu, 15-Feb 7:00 AM ET)
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Blueprint Medicines trades on the NASDAQ stock market under the symbol BPMC.
As of May 13, 2024, BPMC stock price climbed to $108.05 with 361,355 million shares trading.
BPMC has a beta of 1.09, meaning it tends to be more sensitive to market movements. BPMC has a correlation of 0.07 to the broad based SPY ETF.
BPMC has a market cap of $6.77 billion. This is considered a Mid Cap stock.
Last quarter Blueprint Medicines reported $96 million in Revenue and -$1.32 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, BPMC stock traded as high as $117.86 and as low as $37.82.
The top ETF exchange traded funds that BPMC belongs to (by Net Assets): VTI, IWM, VB, VXF, VBK.
BPMC has outperformed the market in the last year with a price return of +100.4% while the SPY ETF gained +27.8%. BPMC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +41.2% and +16.2%, respectively, while the SPY returned +4.3% and +2.5%, respectively.
BPMC support price is $103.20 and resistance is $110.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BPMC stock will trade within this expected range on the day.